Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab Combinations in Ovarian Cancer (OPAL)
NCT03574779Phase 2Completed
- Start
- Nov 2018
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of niraparib and dostarlimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 cohorts). Primary endpoints: Number of Participants Enrolled Across Cohorts at Day 1 and Objective Response Rate. Started Nov 2018; status: completed.
02
Drugs
niraparibdostarlimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT03574779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574779.